Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study

OBJECTIVE: To investigate the long-term safety and tolerability of a once-daily, dual-release hydrocortisone (DR-HC) tablet as oral glucocorticoid replacement therapy in patients with primary adrenal insufficiency (AI). DESIGN: Prospective, open-label, multicenter, 5-year extension study of DR-HC co...

Descripción completa

Detalles Bibliográficos
Autores principales: Nilsson, Anna G, Bergthorsdottir, Ragnhildur, Burman, Pia, Dahlqvist, Per, Ekman, Bertil, Engström, Britt Edén, Ragnarsson, Oskar, Skrtic, Stanko, Wahlberg, Jeanette, Achenbach, Heinrich, Uddin, Sharif, Marelli, Claudio, Johannsson, Gudmundur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425941/
https://www.ncbi.nlm.nih.gov/pubmed/28292927
http://dx.doi.org/10.1530/EJE-17-0067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425941/
https://www.ncbi.nlm.nih.gov/pubmed/28292927
http://dx.doi.org/10.1530/EJE-17-0067

Ejemplares similares